Abstract
Tardive dyskinesia is an abnormal, involuntary, and repetitive movement disorder that occurs during treatment with antipsychotic drugs. Although its pathophysiology has not been fully elucidated, it is usually a late-onset and chronic condition that significantly affects quality of life. A small number of cases of tardive dyskinesia have been reported in patients treated with aripiprazole as antipsychotic medication. The majority of case reports involve adult patients, while reports of tardive dyskinesia following aripiprazole treatment in children and adolescents remain limited. In this case report, the side effect of tardive dyskinesia, which developed following long-term aripiprazole use and regressed rapidly after drug discontinuation, was discussed in a 16-year-old patient who was follow-up with the diagnoses of major depressive disorder and dissociative disorder.
Keywords: Antipsychotic, aripiprazole, child and adolescent, tardive dyskinesia, side effect
References
Tenback DE, van Harten PN. Epidemiology and risk factors for (tardive) dyskinesia. Int Rev Neurobiol. 2011;98:211-230.
Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008;21:151-156.
Correll CU, Kane JM. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. J Child Adolesc Psychopharmacol. 2007;17:647-656.
Demirkol ME, Şenbayram Ş, Doğangüneş G, Tamam L. Tardif diskinezi ve tedavi yaklaşımları. Psikiyatr Güncel Yaklaşımlar. 2018;10:239-254.
Çelik GG, Tahiroğlu A, Avcı A. Çocuk ve ergenlerde atipik antipsikotik ilaçların metabolik ve endokrin yan etkileri. Psikiyatride Güncel Yaklaşımlar. 2011;3:232-250.
Garcia-Amador M, Merchán-Naranjo J, Tapia C, Moreno C, Castro-Fornieles J, Baeza I, de la Serna E, Alda JA, Muñoz D, Andrés Nestares P, Cantarero CM, Arango C. Neurological adverse effects of antipsychotics in children and adolescents. J Clin Psychopharmacol. 2015;35:686-693.
Casey DE. Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry. 2004;65(Suppl 9):25-28.
Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28:1400-1411.
Di Sciascio G, Riva MA. Aripiprazole: from pharmacological profile to clinical use. Neuropsychiatr Dis Treat. 2015;11:2635-2647.
Kirino E. Efficacy and safety of aripiprazole in child and adolescent patients. Eur Child Adolesc Psychiatry. 2012;21:361-368.
Gupta S, Mosnik D, Black DW, Berry S, Masand PS. Tardive dyskinesia: review of treatments past, present, and future. Ann Clin Psychiatry. 1999;11:257-266.
Lamberti M, Di Rosa G, Cucinotta F, Pironti E, Galati C, Gagliano A. Aripiprazole-induced tardive dyskinesia in 13 years old girl successfully treated with biperiden: a case report. Clin Psychopharmacol Neurosci. 2017;15:285-287.
Guy W. Abnormal involuntary movement scale (AIMS). ECDEU Assessment Manual for Psychopharmacology. 1976.
Wonodi I, Reeves G, Carmichael D, Verovsky I, Avila MT, Elliott A, Hong LE, Adami HM, Thaker GK. Tardive dyskinesia in children treated with atypical antipsychotic medications. Mov Disord. 2007;22:1777-1782.
Balıbey H, Yaşar H, Tekeli H. A case report of tardive dyskinesia and tremor due to use of aripiprazole. Klin Psikofarmakol Bul. 2011;21:262-264.
Heitzmann E, Javelot H, Weiner L, Michel B. A case of aripiprazole-induced tardive dyskinesia with dramatic evolution. Case Rep Psychiatry. 2016;7031245.
Goyal R, Devi SH. A case of aripiprazole induced tardive dyskinesia in a neuroleptic-naïve patient with two years of follow up. Clin Psychopharmacol Neurosci. 2014;12:69-71.
Aguilar L, Lorenzo C, Fernández-Ovejero R, Roncero C, Montejo AL. Tardive dyskinesia after aripiprazole treatment that improved with tetrabenazine, clozapine, and botulinum toxin. Front Pharmacol. 2019;10:281.
